Effects of the Aqueous Extracts of *Rhodamnia cinerea* on Metabolic Indices and Sorbitol-Related Complications in Type 2 Diabetic Rats

(Kesan Ekstrak Akues *Rhodamnia cinerea* terhadap Indeks Metabolik dan Komplikasi Berkaitan Sorbitol dalam Tikus Diabetik Jenis 2)

MUSTAPHA UMAR IMAM, MAZNAH ISMAIL* & SASIKALA M CHINNAPPAN

ABSTRACT

There is growing interest in the use of plant bioresources for managing Type 2 diabetes. In this study, *Rhodamnia cinerea*, which is used traditionally to manage diseases in Malaysia, was explored for its antidiabetic effects. Type 2 diabetic rats were managed for 4 weeks using aqueous extract of *R.* cinerea or quercetin. Weights and fasting glucose were measured weekly, while serum lipid profiles, insulin, antioxidant status, urea, creatinine and liver enzymes were assayed at the end. Sorbitol contents, antioxidant capacities and aldose reductase activities of the kidney, lens and sciatic nerve were also assessed. The results showed that the aqueous extract of *R.* Cinerea mainly contained Myricitrin and it reduced glycemia (p > 0.05), lipid profiles (p < 0.05), F2-isoprostanes (p < 0.05) and overall metabolic condition of type 2 diabetic rats. *R.* cinerea also attenuated sorbitol contents of the nerve (p < 0.05) and kidney (p < 0.05), partly through regulating the activity of aldose reductase (p < 0.05 for nerve) and sorbitol dehydrogenase (p < 0.05 for kidney) in comparison with diabetic untreated group. Quercetin is a known aldose reductase inhibitor and can improve several metabolic indices related to Type 2 diabetes. In this study, the results of *R.* cinerea were comparable to or better than those of quercetin, suggesting that *R.* cinerea extract can be a good candidate for managing Type 2 diabetes and its complications related to sorbitol accumulation.

Keywords: Aldose reductase; *Rhodamnia cinerea*; sorbitol; Type 2 diabetes

INTRODUCTION

There is a growing burden of Type 2 diabetes globally, which is driving the efforts for more effective ways to manage this disease. Moreover, currently available therapeutic options have so far fallen short of effectively managing the disease, due to side effects and narrow spectrum of activity that does not cover the multiple metabolic perturbations in this disease (Gurib-Fakim 2006; World Health Organization 2014). This has heightened interest in plant bioresources, which are seen as safer and more cost-effective options when compared with pharmaceutical agents. There is enough biodiversity in many countries to provide potential candidate plants with such medicinal potentials. Thus, there is an increasing drive to study plants that have hitherto been unexplored for their medicinal properties, which is what this study aimed to achieve. In particular, Malaysia is rich in biodiversity, and thus there has been an increasing drive to study plants with...
potential anti-diabetic and other beneficial effects, some of which are already used as traditional medicine, in order to provide evidence-based justification for their usage (Adam et al. 2011; Nasir et al. 2015; Rahim et al. 2014).

*R. cinerea*, which belongs to the myrtle family, comprises of a group of rainforest trees and shrubs that are characterized by fleshy fruits (Govaerts et al. 2008). Their leaves are small and oblong, measuring around 2-7 cm. Not much is known regarding the medicinal properties of *R. cinerea*, although its leaves and roots are used for traditional medicine (Keng 1990; Scott 1979). Additionally, we recently observed for the first time that the aqueous extract of the plant had anti diabetic potentials using in vitro and in vivo testing, which has been filed for patent (Gehling et al. 2015). Thus, we hypothesized that the aqueous extract of *R. Cinerea* could improve metabolic indices, organ-specific sorbitol contents and organ-specific aldose reductase activities in Type 2 diabetic rats, which was tested in this study.

**MATERIALS AND METHODS**

**MATERIALS**

Aldose reductase, F2-isoprostanes and Insulin ELISA kits were purchased from Elabscience Biotechnology Co. Ltd (Wuhan, China), while the deproteinization kit and total sorbitol content kit were purchased from Biovision (Mountain View, CA, USA) and Sigma Chemical Co. (St. Louis, Missouri, USA), respectively. RCL2® Solution was purchased from ALPHELYS (Toulouse, France). Kits for biochemical analyses were purchased from Randox Laboratories Ltd (Crumlin, County Antrim, UK). The sugar and starch powders were purchased from R & S Marketing Sdn. Bhd. (Malaysia), while the Palm Oil, Nespray fortified milk powder and standard rat chow were purchased from Unilever (Malaysia), Nestle Manufacturing (Malaysia) and Specialty Feeds (TN, USA), respectively. Myricitrin reference standard (C21H20O12, CAS# 17912-87-7) was purchased from ChromaDex (CA, USA). Other chemicals and quercetin were purchased from Sigma-Aldrich Chemical (USA) and Thermo Fisher Scientific (Massachusetts, USA).

**PLANT MATERIAL**

*R. cinerea* was purchased from RD Agro Herbs, Serdang, Malaysia, and authenticated (voucher specimen PID 170414-13) by Mr. Kamarudin Saleh from (Forest Research Institute Malaysia).

**SOLVENT EXTRACTION**

The collected plant was washed several times with running tap water followed by deionized water and the aerial parts (leaves and stems) were dried for 4 days. The dried material was cut into smaller pieces and passed through a mesh opening of 6.0 mm sieve (Retisch SM 100, Germany). They were then mixed with water in the ratio of 1:10 and heated using hot plate for 3 h at 100°C. The mixtures were subsequently filtered through cotton wool (source and any spec) and the solvents were removed under reduced pressure (Rotavapor R210, Buchi, Switzerland) followed by spray drying (Buchi mini spray drier B-290, Switzerland). The dried crude extracts were stored at room temperature until further analysis.

**HPLC ANALYSIS OF EXTRACT**

HPLC analysis was performed using Agilent 1200 series linked with diode array detector (Agilent, Stevens Creek Blvd Santa Clara, USA). Chromatographic separations were performed on a Phenomenex Kinetex, Analytical column (2.1 x 150 mm, 1.7μm). The mobile phase was composed of solvent (A) 0.1% formic acid in water and solvent (B) 0.1% formic acid in acetonitrile, with the respective solvent gradient: 95 and 5% (0 min), 95 and 5% (3 min), 80 and 20% (8 min), 80 and 20% (16 min), 60 and 40% (22 min), 0 and 100% (25 min), 0 and 100% (30 min) and 5 and 95% (33 min). A flow rate of 0.3 mL/ min was used and 2 μL of sample was injected. The samples and mobile phases were filtered through a 0.22 μm Millipore filter, type GV (Millipore, Bedford, MA) prior to HPLC injection. Each extract and fraction was analyzed in three replicates. Myricitrin was identified and quantified by comparing its retention times with authenticated standard (C21H20O12, CAS# 17912-87-7).

**ANIMAL HANDLING**

Approval for use of animals was sought from the Animal Care and Use Committee (ACUC) of the Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (Project approval number: UPMP/ACUC/IAP-R045/2013) and the set guidelines for the use of animals were strictly adhered to. The animals (Sprague dawley rats, 10 weeks old, weighing 200-250 g, n=25) were obtained from Veterinary Medicine Faculty, Universiti Putra Malaysia and placed in plastic cages (two per cage). They were given free access to normal rat chow and water for 2 weeks to acclimatize under controlled conditions (25-30 °C, with a 12/12 h light/dark cycle). Thereafter, some rats (5 rats) were maintained on normal rat chow (normal group), while others were fed with high fat diet for 8 weeks and injected with streptozotocin (STZ) intraperitoneally (35 mg/kg in sodium citrate buffer, pH 4.5) to induce Type 2 diabetes (Imam & Maznah 2013). The normal group also received 5 mmol/L of sodium citrate buffer, pH 4.5 intraperitoneally. The diabetic rats (fasting plasma glucose of ≥ 250 mg/dl after 2 days of STZ) were divided into 4 groups (n=5); diabetic untreated, 100 mg/kg/day *R. cinerea* extract, 200 mg/kg/day *R. cinerea* extract and quercetin (10 mg/kg/day) groups. Food intake was maintained at 30 kcal/100 g body weight/day for 4 weeks after injection of STZ. Weekly measurements of weight and fasting blood glucose were made using a laboratory measuring scale and glucometer, respectively. During sacrifice, fasting blood and tissue samples (liver, kidney, lens and sciatic
nerves) were collected for further tests. The tissues were immediately washed with ice-cold saline and stored in RCL2® Solution (ALPHELYS, France) at -80°C, while the blood was centrifuged at 3000 rpm for 10 min at 4°C to separate the serum.

**BIOCHEMICAL ANALYSES**

Kidney (urea and creatinine) and liver function (alanine transamine (ALT), aspartate transmaine (AST), alkaline phosphatase (ALP)) markers, and lipid profiles (total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) and triglyceride (Trig)) were analyzed on Clinical Chemistry Analyzer (Vita Scientific, Dieren, The Netherlands).

Insulin and F2-isoprostane levels were measured from the serum samples collected, while liver samples were homogenized in cold phosphate buffered saline (1X PBS, pH 7.4), centrifuged at 7000 rpm for 5 min and the supernatant used for total antioxidant status measurements using ELISA kits (Elabscience Biotechnology Co. Ltd, Wuhan, China) according to manufacturer’s instructions. Absorbances were read on BioTek Synergy H1 Hybrid Reader (BioTek Instruments Inc., Winooski, VT, USA), and the results were analyzed on www.myassays.com (insulin, $R^2 = 0.9954$; F2-isoprostane, $R^2 = 0.984$; Antioxidant status, $R^2 = 0.94$).

**DATA ANALYSIS**

Data are presented as means ± SD (n=5). The normality of the distribution of the data was confirmed using the Shapiro-wilk normality test prior to one-way analysis of variance (ANOVA) on SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Differences between means were considered significant when $p<0.05$.

**RESULTS AND DISCUSSION**

The use of plants for managing diseases has been practised for a long time, although in recent years there is renewed interest in plant resources due to concerns of side effects and cost of pharmaceutical agents (Gurib-Fakim 2006; Ismail & Imam 2014). In this study, we explored the potential antidiabetic effects of R. cinerea. The results showed that there was progressive decrease in glycemia in the R. cinerea-treated groups, although no significant difference was observed compared to the diabetic untreated group (Table 1). Improved glycemia suggested that the plant extract is able to regulate the sustained chronic hyperglycemia, which is the hallmark of Type 2 diabetes (Stumvoll et al. 2005), albeit not through improved insulin secretion (Table 2). Also, there was marked reduction in the weight of the diabetic untreated group ($p<0.05$) between the baseline $311 ± 20$ g and week 4 ($257 ± 38$ g) (Table 1), which can be attributed to gluconeogenesis. In Type 2 diabetes, when body cells cannot take up glucose from the blood glucose and body weight changes over 4 weeks of intervention.

<table>
<thead>
<tr>
<th>Rat groups</th>
<th>Glucose (mmol/L)</th>
<th>Weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 1</td>
</tr>
<tr>
<td>R. cinerea 100 mg</td>
<td>18.7 ± 3.3 a</td>
<td>14.6 ± 0.6 a</td>
</tr>
<tr>
<td>R. cinerea 200 mg</td>
<td>17.9 ± 3.6 a</td>
<td>18.3 ± 2.0 a</td>
</tr>
<tr>
<td>Quercetin</td>
<td>19.8 ± 4.1 a</td>
<td>14.6 ± 3.4 a</td>
</tr>
<tr>
<td>Diabetic untreated</td>
<td>18.2 ± 0.8 a</td>
<td>15.2 ± 1.8 a</td>
</tr>
<tr>
<td>Normal</td>
<td>4.7 ± 0.5</td>
<td>4.2 ± 0.2</td>
</tr>
</tbody>
</table>

Data are mean ± SD (n=5). The normal group was fed normal pellet throughout the intervention, while the diabetic untreated group (high fat diet + 35 mg/kg streptozotocin) received high fat diet for 4 weeks. The quercetin, R. cinerea 100mg and R. cinerea 200 mg groups received quercetin (10 mg/kg/day) and 100 mg/kg/day and 200 mg/kg/day of aqueous extract of R. cinerea in addition to the high fat diet for 4 weeks after diabetes induction. *indicates statistical difference in comparison with the normal group for either glucose or weight measurements in each column ($p<0.05$).
blood due to insulin insensitivity, endogenous production of glucose in the liver is increase from fats and proteins broken down from body stores (Magnarsson et al. 1992). This may explain the marginal decrease in body weight in the quercetin group since quercetin has been shown to inhibit gluconeogenesis (Gasparini et al. 2003). Although there was weight reduction in the R. cinerea groups, it may have been due to weight-reducing properties of the extracts as suggested by the high dose use in this study, which was able to reduce the weights beyond that of the diabetic untreated group.

**R. CINEREA IMPROVED LIPID PROFILES, OXIDATIVE STRESS, AND LIVER AND KIDNEY FUNCTIONS**

Lipid profile, liver and kidney functions are dysregulated in Type 2 diabetes (Imam et al. 2013, 2012). In this study, R. cinerea significantly improved lipid profiles (Table 2) indicating that it may be able to prevent diabetes related cardiovascular diseases, which is an important cause of morbidity and mortality in Type 2 diabetes (Elkeles et al. 1998). Moreover, the worsened liver and kidney function were improved by R. cinerea (Table 2) also suggesting the ability of the extract to improve overall metabolic condition and its lack of toxicity in diabetes. The attenuation of oxidative stress in the liver as evidenced by reduced F2-isoprostane (Roberts & Morrow 2000) in comparison with the untreated diabetic group (Table 2, p<0.05) further corroborates the improvement in overall metabolic condition of the diabetic rats as a result of feeding the R. cinerea extract.

**R. CINEREA ATTENUATED ALDOSE REDUCTASE ENZYME ACTIVITY**

Sorbitol contents (Table 2) of the lens, nerve and kidney were elevated in the untreated group, while quercetin, which is known to lower sorbitol levels (Kador et al. 1985), showed reduced levels in the lens and kidney (p<0.05). R. cinerea extract also reduced the sorbitol contents, especially of the kidney and nerve (p<0.05), which indicated that it may prevent sorbitol-related complications in type 2 diabetes including diabetic nephropathy and neuropathy. Because the activity of aldose reductase has been shown to influence sorbitol levels (Kador et al. 1985), we assayed the activities in the lens, kidney and nerve (Table 2). The results showed that the aldose reductase activities of the lens and nerve were significantly increased in the diabetic untreated group in comparison with the normal group, while the R. cinerea and quercetin groups attenuated these increases (p<0.05). The reduced aldose reductase activities in the lens and nerves of the R. cinerea groups likely contributed to the lower sorbitol contents in these tissues (Yabe-Nishimura 1998), although other factors including the metabolic flux due to blood glucose may have played a role in the case of the kidney (Gabbay 1975), which showed lower sorbitol content but not aldose reductase activity. Similarly, the ability of the extract to regulate oxidative stress in these tissues may have played a role in the regulation of sorbitol. It has been demonstrated that increased oxidative stress propagates the buildup of sorbitol and other complications in Type 2 diabetes (Dey & Lakshmanan 2013; Rahimi et al. 2005) and the results from this study showed that the untreated diabetic control group had lower antioxidant capacities in the lens, kidney and nerve (Table 2), while the R. cinerea-treated groups had improved antioxidant capacities, although only those of the kidney were significant different (p<0.05).

**HPLC BIOACTIVE IDENTIFICATION**

The active compound identified in the aqueous extract of R. cinerea was myricetrin (1.013 ± 0.003% w/w extract), which is a flavonol rhamnoside of myricetin that is broken down to myricetin in the intestine (Smith & Griffiths 1970), although some of it is converted to a myricitrin glycoside prior to absorption (Matsukawa et al. 2012). Myricetin has been shown to regulate intestinal glucose uptake (Postal et al. 2014) and weight gain (Maronpot et al. 2015), while its metabolite (myricetrin) is widely acknowledged to have antidiabetic properties mediated via improvements in glycemia, weight and lipid profiles, antioxidation and aldose reductase inhibition (Li & Ding 2012; Ong & Khoo 1997), similar to the effects observed in this study.

In aggregate, our data showed that R. Cinerea could improve metabolic perturbations in Type 2 diabetic rats. Although some results were not significantly different between the R. cinerea-treated groups and the diabetic untreated group, perhaps longer treatment period could have produced more significant changes as indicated by the trend of improvements in the R. Cinerea groups. Therefore, R. cinerea can be a good candidate for diabetes management. Moreover, the inability of pharmaceutical agents to effectively prevent complications is the basis for the failure to effectively curb the burden of diabetes. These results suggested that the traditional use of R. cinerea for managing diseases may have been based on its ability to regulate multiple biochemical parameters as shown in the present study. Hence, R. cinerea has medicinal properties that can be developed into nutraceuticals for management of diabetes and its complications.

**CONCLUSION**

Type 2 diabetic rats treated with an aqueous extract of R. cinerea showed improved glycemia, lipid profiles and kidney and liver function markers. R. cinerea also regulated the activity aldose reductase and produced lower sorbitol contents of the nerve and kidney. Overall, the results of R. cinerea were comparable or even better than those of quercetin. Thus, R. cinerea extract can be a good candidate for the management of diabetic complications and other related metabolic disorders with lipid abnormalities and oxidative stress. However, there is need for long term studies to establish the translational implications of these findings.
<table>
<thead>
<tr>
<th>Parameter</th>
<th>R. cinerea (100 mg/kg)</th>
<th>R. cinerea (200 mg/kg)</th>
<th>Quercetin (10 mg/kg/day)</th>
<th>Diabetic untreated</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin (pg/mL)</td>
<td>140 ± 10 *</td>
<td>143 ± 10 *</td>
<td>140 ± 10 *</td>
<td>125 ± 32 *</td>
<td>265 ± 24</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>1.3 ± 0.32 b</td>
<td>1.3 ± 0.11 b</td>
<td>1.3 ± 0.03 a</td>
<td>1.2 ± 0.12</td>
<td>1.2 ± 0.12</td>
</tr>
<tr>
<td>Trig (mmol/L)</td>
<td>0.8 ± 0.11 b</td>
<td>0.6 ± 0.06 b</td>
<td>0.3 ± 0.07 b</td>
<td>0.4 ± 0.02 a</td>
<td>0.2 ± 0.06</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>0.3 ± 0.05 b</td>
<td>0.3 ± 0.06 b</td>
<td>0.3 ± 0.07 b</td>
<td>0.4 ± 0.02 a</td>
<td>0.2 ± 0.06</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>0.8 ± 0.19</td>
<td>0.8 ± 0.10</td>
<td>0.8 ± 0.16</td>
<td>0.7 ± 0.09 a</td>
<td>0.9 ± 0.05</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>69.0 ± 18.3</td>
<td>68 ± 18.3</td>
<td>73 ± 19.8</td>
<td>90.1 ± 36.39</td>
<td>57.6 ± 12.46</td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>362.5 ± 56.4 a</td>
<td>362.5 ± 56.4 a</td>
<td>211 ± 72.43 a,b</td>
<td>454 ± 11.55 a</td>
<td>126.3 ± 4.74</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>129.5 ± 37.3</td>
<td>127.7 ± 24.1</td>
<td>148.3 ± 60.44</td>
<td>188.1 ± 50.9</td>
<td>149.9 ± 31.12</td>
</tr>
<tr>
<td>Crea (umol/L)</td>
<td>64.1 ± 9.6</td>
<td>63.2 ± 5.50</td>
<td>67 ± 7.75</td>
<td>72.5 ± 10.76</td>
<td>60.5 ± 3.51</td>
</tr>
<tr>
<td>Urea (mmol/L)</td>
<td>6.6 ± 2.7</td>
<td>7.5 ± 1.60 a</td>
<td>5.5 ± 1.23</td>
<td>6.8 ± 0.56 a</td>
<td>4.2 ± 0.88</td>
</tr>
<tr>
<td>Liver TAS (ng/mg tissue)</td>
<td>7.63 ± 0.5</td>
<td>7.82 ± 0.66</td>
<td>7.89 ± 0.63</td>
<td>7.27 ± 0.36</td>
<td>7.82 ± 0.31</td>
</tr>
<tr>
<td>Serum F2-isoprostane (pg/mL)</td>
<td>45.0 ± 4.0 a</td>
<td>31.0 ± 8.0 b</td>
<td>30.1 ± 9.3 b</td>
<td>67.5 ± 18.1 a</td>
<td>9.5 ± 1.6</td>
</tr>
<tr>
<td>Sorbitol (ng/mg tissue)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lens</td>
<td>206.6 ± 16.6</td>
<td>200.8 ± 9.2</td>
<td>181.7 ± 9.0 a</td>
<td>224.4 ± 25.9</td>
<td>199.3 ± 31.6</td>
</tr>
<tr>
<td>Kidney</td>
<td>203.2 ± 4.0 b</td>
<td>185.3 ± 4.2 a,b</td>
<td>187.0 ± 6.9 b</td>
<td>220.6 ± 7.8 a,b</td>
<td>156.8 ± 5.1</td>
</tr>
<tr>
<td>Nerve</td>
<td>205.1 ± 9.9</td>
<td>178.5 ± 4.4 a,b</td>
<td>222.0 ± 0.6 a</td>
<td>213.9 ± 0.8</td>
<td>210.5 ± 12.2</td>
</tr>
<tr>
<td>Aldose reductase (ng/100mg tissue)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lens</td>
<td>44.2 ± 7.9 b</td>
<td>8.3 ± 1.0 a,b</td>
<td>502.8 ± 8.7 b</td>
<td>544.7 ± 18.6 a</td>
<td>8.3 ± 1.0</td>
</tr>
<tr>
<td>Kidney</td>
<td>8.3 ± 2.0</td>
<td>10.8 ± 3.9</td>
<td>8.3 ± 3.0</td>
<td>8.3 ± 5.0</td>
<td>8.3 ± 3.0</td>
</tr>
<tr>
<td>Nerve</td>
<td>224.5 ± 50.0 b</td>
<td>135.1 ± 50.0 b</td>
<td>8.3 ± 0.5 a</td>
<td>7645.5 ± 1004.0 a</td>
<td>8.3 ± 0.5</td>
</tr>
<tr>
<td>Total antioxidant status (ng/mg tissue)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lens</td>
<td>5.9 ± 0.6 a</td>
<td>5.9 ± 0.8 a</td>
<td>6.4 ± 1.1 a</td>
<td>4.8 ± 1.1 a</td>
<td>6.9 ± 0.2</td>
</tr>
<tr>
<td>Kidney</td>
<td>8.8 ± 1.6 a</td>
<td>9.0 ± 0.9 a</td>
<td>7.5 ± 1.4 a</td>
<td>4.1 ± 0.3 a</td>
<td>9.1 ± 1.1</td>
</tr>
<tr>
<td>Nerve</td>
<td>14.3 ± 0.9 a</td>
<td>15.1 ± 3.0</td>
<td>16.7 ± 1.0 a</td>
<td>11.9 ± 2.9 a</td>
<td>16.7 ± 0.4</td>
</tr>
</tbody>
</table>

Data are mean ± SD (n=5). Groups are the same as Table 1. * indicates statistical difference in comparison with the normal in each row (p<0.05). a, b indicate statistical difference in comparison with the diabetic untreated normal group in each row (p<0.05). TC: total cholesterol; Trig: triglyceride; LDL: low density lipoprotein; HDL: high density lipoprotein; ALT: alanine transaminase; AST: aspartate transaminase; Crea: creatinine; TAS: Total antioxidant status.
ACKNOWLEDGEMENTS

The authors thank the staff of the Laboratory of Molecular Biomedicine for their assistance with this study.

REFERENCES


Mustapha Umar Imam & Maznah Ismail* Laboratory of Molecular Biomedicine, Institute of Bioscience Universiti Putra Malaysia 43400 UPM Serdang, Selangor Darul Ehsan Malaysia
Maznah Ismail*
Department of Nutrition and Dietetics
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
43400 UPM Serdang, Selangor Darul Ehsan
Malaysia

Sasikala M Chinnappan
Biotropics Malaysia Berhad, Jalan Pantai Baharu
50672 Kuala Lumpur, Federal Territory
Malaysia

*Corresponding author; email: maznahis@upm.edu.my
Received: 26 November 2015
Accepted: 29 September 2016